PGGM Investments increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 9.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 725,684 shares of the medical research company’s stock after buying an additional 64,011 shares during the period. PGGM Investments’ holdings in Amgen were worth $110,413,000 at the end of the most recent quarter.
Several other institutional investors also recently made changes to their positions in AMGN. Bank of Montreal Can bought a new position in shares of Amgen during the second quarter valued at about $383,036,000. Wellington Management Group LLP boosted its position in shares of Amgen by 16.0% in the first quarter. Wellington Management Group LLP now owns 13,544,922 shares of the medical research company’s stock valued at $2,030,789,000 after buying an additional 1,864,688 shares during the last quarter. Nordea Investment Management AB boosted its position in shares of Amgen by 37.1% in the second quarter. Nordea Investment Management AB now owns 5,719,168 shares of the medical research company’s stock valued at $870,171,000 after buying an additional 1,547,099 shares during the last quarter. NN Investment Partners Holdings N.V. bought a new position in shares of Amgen during the first quarter valued at about $113,507,000. Finally, UBS Asset Management Americas Inc. boosted its position in shares of Amgen by 12.4% in the first quarter. UBS Asset Management Americas Inc. now owns 3,712,647 shares of the medical research company’s stock valued at $556,636,000 after buying an additional 409,863 shares during the last quarter. Institutional investors and hedge funds own 79.15% of the company’s stock.
Shares of Amgen Inc. (NASDAQ:AMGN) traded up 0.32% on Monday, reaching $167.34. The company had a trading volume of 2,514,609 shares. Amgen Inc. has a 12 month low of $138.06 and a 12 month high of $176.85. The company has a market capitalization of $125.23 billion, a price-to-earnings ratio of 17.12 and a beta of 0.94. The stock has a 50 day moving average price of $171.51 and a 200-day moving average price of $161.44.
Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, July 27th. The medical research company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.74 by $0.10. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The firm had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.58 billion. During the same period last year, the firm earned $2.57 EPS. The firm’s revenue was up 5.9% compared to the same quarter last year. Analysts forecast that Amgen Inc. will post $11.36 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, September 8th. Investors of record on Wednesday, August 17th were given a $1.00 dividend. This represents a $4.00 annualized dividend and a yield of 2.39%. The ex-dividend date of this dividend was Monday, August 15th. Amgen’s dividend payout ratio is currently 40.90%.
AMGN has been the subject of several recent analyst reports. BMO Capital Markets restated a “buy” rating and set a $186.00 target price on shares of Amgen in a research note on Tuesday, July 12th. Vetr upgraded Amgen from a “sell” rating to a “hold” rating and set a $165.78 target price for the company in a research note on Wednesday, July 27th. Leerink Swann restated a “hold” rating on shares of Amgen in a research note on Saturday, September 17th. Zacks Investment Research cut Amgen from a “buy” rating to a “hold” rating in a research note on Monday, August 1st. Finally, Goldman Sachs Group Inc. restated a “buy” rating and set a $206.00 target price (up previously from $204.00) on shares of Amgen in a research note on Tuesday, September 27th. One analyst has rated the stock with a sell rating, nine have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Amgen has a consensus rating of “Buy” and an average price target of $185.06.
In related news, VP Annette Louise Such sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total value of $523,770.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.20% of the stock is owned by corporate insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.